BRCA2 and cancer: RRSO has proven efficacy, with a reduction in “ovarian cancer” risk of 79–85% [11–13], and it is associated with lower cancer-specific and all-cause mortality in BRCA1 and BRCA2 mutation carriers [13, 14].